GE HealthCare Faces Securities Investigation Following Earnings Miss

The scrutiny centers on the company’s performance disclosures from April 29, 2026, when GE HealthCare reported adjusted earnings per share of $0.99. During the same announcement, management revised its full-year 2026 adjusted EPS guidance downward to a range of $4.80 to $5.00, citing a recall involving a pharmaceutical diagnostics supplier and margin declines in its patient care solutions division. The resulting market reaction saw the stock price tumble by $9.01, closing at $59.49.

Investor concerns have been compounded by subsequent leadership changes. On July 23, 2026, the company confirmed that Chief Financial Officer Jay Saccaro would step down from his position. The firm is now operating under an interim CFO while conducting a search for a permanent successor. Investors seeking to participate in the ongoing investigation or discuss their legal rights can contact the Law Offices of Howard G. Smith in Bensalem, Pennsylvania, via telephone at 215-638-4847 or through their website.